Company grows management team in preparation for the launch of their AI-driven algorithm for the diagnostic of Parkinson’s Disease.
GAINESVILLE, FL – neuropacsTM, a leading innovator in AI-driven neurological diagnostics, today announced that Martin Handfield, MS, PhD, will serve as President and Chief Executive Officer, effective immediately.
Dr. Handfield is a local serial entrepreneur, having served in a variety of private and public startup companies in the life science industry for the last 26 years. During his academic and corporate career, he led the scientific, pre-clinical and clinical development of multiple classes of diagnostics and therapeutics, including antibiotics, vaccines and live bacterial therapeutics, several of which were first-in-man or new biological entities at the FDA/EMEA. Most recently, Martin served as the Chief Scientific Officer (CSO) at Oragenics (NYSE:OGEN) and is currently serving as an Entrepreneur-in-Residence at the University of Florida (UF-Innovate/Venture).
”Dr. Handfield is the right recruit for neuropacsTM. He brings decades of translational academic research and business experience, key attributes to bring our first AI-derived software to the clinic”, commented co-Founders David Vaillancourt, PhD (CSO) and Angelos Barmpoutis, PhD (CTO). Handfield added: “I’m thrilled with the opportunity to contribute to neuropacs’ mission, and I believe that our innovative approach is a large and untapped market opportunity that has the potential to transform how several neurodegenerative diseases are diagnosed, ultimately paving the way for earlier intervention and improved patient outcomes.”
For more information about neuropacsTM and its revolutionary diagnostic solutions, visit neuropacs.com.
About neuropacsTM:
neuropacsTM is a pioneering neurological technology company dedicated to developing innovative AI-driven diagnostics. With a commitment to advancing healthcare through cutting-edge technologies, neuropacsTM remains at the forefront of revolutionizing clinical care standards.
Forward-Looking Statements
This communication includes express and implied “forward-looking statements.” Forward-looking statements include all statements that are not historical facts and in some cases, can be identified by terms such as “may,” “might,” “will,” “could,” “would,” “should,” “expect,” “intend,” “plan,” “objective,” “anticipate,” “believe,” “estimate,” “predict,” “potential,” “continue,” “ongoing,” or the negative of these terms, or other comparable terminology intended to identify statements about the future. By their nature, these statements are subject to numerous risks and uncertainties, that could cause actual results, performance or achievement to differ materially and adversely from those anticipated or implied in the statements. You should not rely upon forward-looking statements as predictions of future events. Although our management believes that the expectations reflected in our statements are reasonable, we cannot guarantee that the future results, performance, or events and circumstances described in the forward-looking statements will be achieved or occur. Recipients are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date such statements are made and should not be construed as statements of fact. We undertake no obligation to publicly update any forward-looking statements, whether as a result of new information, any future presentations, or otherwise, except as required by applicable law.